Updated:
Vibe Biotechnology
Vibe Biotechnology runs a multi-site computational drug discovery platform with integrated wet labs in Mountain View, Budapest, and Manchester.
Vibe Biotechnology
Vibe Biotechnology was founded as a therapeutics company focused on applying modern machine learning techniques to drug discovery. The firm operates research hubs in Mountain View, Budapest, and Manchester, with additional offices in Boston and Jackson, Wyoming. This multi-site structure allows Vibe to integrate computational biology workflows developed in Silicon Valley with wet-lab validation capacity in Europe — a logistical architecture more typical of distributed software engineering teams than traditional biotech startups. Vibe's strategy centers on identifying and validating preclinical drug candidates using AI-driven prediction models. The firm works across multiple therapeutic areas, including neurodegenerative disease, oncology, and age-related conditions. Its computational platform screens molecular libraries in silico before advancing the most promising candidates to in vitro and in vivo testing at its own laboratory facilities. By internalizing both the algorithmic and biological validation steps, Vibe compresses the feedback loop between computational prediction and empirical result — a cycle that typically fractures across separate CROs and academic labs. The firm may partner with larger pharmaceutical companies on later-stage clinical development, though specifics remain undisclosed. Vibe maintains offices on both US coasts, a European R&D presence, and a secondary US location in Jackson, Wyoming — a footprint that suggests both scientific and investor-oriented hubs. The firm has not disclosed total headcount, capital raised, or specific fund structures. Its geographic spread across biotech centers and lower-cost regions reflects the dual pressures of accessing top-tier computational talent and managing the capital-intensive reality of laboratory operations. The Boston office places Vibe in proximity to the dense Kendall Square biotech ecosystem, while the Wyoming presence may relate to operational or investor-relations functions. The structural differentiator is Vibe's wholly-owned, multi-continent laboratory network. Most computational drug discovery startups rely on outsourced CROs or academic partnerships for biological validation — Vibe runs its own wet labs, giving the firm direct control over experimental design, data generation, and IP provenance. This vertically integrated model is capital-intensive but eliminates the data-quality variability and IP fragmentation that plague CRO-dependent peers. The approach positions Vibe less as a software vendor to pharma and more as an autonomous drug-hunting entity.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Mountain View
Corporate office
Mountain View, CA, United States
Additional offices
Manchester, UK · Budapest, Hungary · Jackson, WY · Boston, MA
Sector focus
Frequently asked questions
How does Vibe Biotechnology's approach to drug discovery differ from traditional pharma R&D?
Vibe integrates machine learning-based candidate screening with in-house wet-lab validation, rather than relying on contract research organizations for biological testing. This closed-loop model aims to accelerate the iteration cycle between computational prediction and experimental confirmation. Traditional pharma typically separates computation and validation across different organizations, introducing data fragmentation and longer timelines.
Which therapeutic areas does Vibe Biotechnology target?
Vibe focuses on neurodegenerative diseases, oncology, and age-related conditions. The firm's computational platform is designed to screen broadly across these areas, but specific lead indications within each category have not been publicly detailed. The therapeutic focus aligns with areas where AI-driven molecular prediction may offer the highest marginal advantage over traditional high-throughput screening.
Why does Vibe maintain laboratories in both Budapest and Manchester?
The European labs provide dedicated wet-lab capacity for biological validation of computational predictions generated in Mountain View. Budapest offers access to strong molecular biology talent at lower operating costs than major US biotech hubs. Manchester provides additional bench capacity and situates the firm within the UK's life sciences ecosystem, which has particular strength in neurodegenerative disease research.
Does Vibe Biotechnology partner with larger pharmaceutical companies?
Vibe may enter co-development or licensing partnerships with larger pharmaceutical firms for clinical-stage development, as its capabilities are concentrated in preclinical discovery and early validation. However, no specific partnership announcements have been identified in public records. A vertically integrated preclinical model typically positions such firms to negotiate from strength on asset out-licensing.
How is Vibe Biotechnology funded?
Vibe's funding structure has not been publicly disclosed. Biotech platforms with integrated lab networks typically raise capital through venture funding, strategic partnerships, or a combination of both. The firm's multi-continent lab footprint suggests significant capital deployment, though no specific funding rounds or backers have been confirmed in available records.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: